MGRC Healthcare and Yayasan Kanser Malaysia Join Forces to Amplify Cancer Awareness and Promote Immunotherapy Solutions

The Partnership Marks a Significant Stride in Cancer Education and Genomic Advancements, Coinciding with Blood Cancer Awareness Month

PETALING JAYA, (06 SEPTEMBER 2023) – As Blood Cancer Awareness Month unfolds this September, Malaysian Genomics Resource Centre Berhad ("MGRC" or "the Group"), a leading genomics and biopharmaceutical specialist, is delighted to announce a pivotal Strategic Collaboration Agreement between its wholly-owned subsidiary, MGRC Healthcare Sdn. Bhd. ("MGRCH"), and Yayasan Kanser Malaysia ("YKM").

The partnership aims to elevate cancer awareness and early detection by merging YKM's community-centric educational programmes with MGRCH’s advanced genomic and immunotherapy services, including cutting-edge CAR T-cells and Natural Killer (NK) cells. (Link for more info)

YKM, a notable foundation devoted to cancer awareness and patient support, aims to serve 10,000 cancer patients within the next five years and has ambitious plans to establish a specialized hospital. Their multi-pronged initiatives range from education to emotional and financial support for cancer patients, solidifying their commitment to fostering a health-conscious community in Malaysia.

In a combined effort, the organisations are poised to roll out a series of comprehensive public awareness campaigns through both physical and digital channels. MGRCH brings its medical genomics expertise to the partnership, providing specialist input and specialty services at these events. YKM will complement this by securing necessary permits and boosting event promotion, thereby ensuring a synergistic, impactful collaboration.

Azri Azerai, Executive Chairman of Malaysian Genomics, enthused, "As we mark Blood Cancer Awareness Month, our collaboration with Yayasan Kanser Malaysia couldn't be timelier. As we possess the only privately-owned BSL 2 GML Certified lab for cell culture, we will create a formidable force against cancer by integrating MGRC's ground-breaking CAR T-cells and Natural Killer (NK) cell therapies into YKM’s robust community outreach programmes. Investors should be acutely aware that this alliance is more than just synergistic; it significantly expands our market reach while showcasing our commitment to advancing immunotherapy solutions in the field of genomics."

In line with this, Dr. Mohd Suhaimi Bin Yaakof, Medical Board YKM stated, "This partnership with MGRC Healthcare represents a vital step in raising public awareness around cancer. Together, we're maximising our collective impact through MGRC’s state-of-the-art genomics and our grassroots community engagement."

This collaboration augments MGRC’s standing in the swiftly evolving genomics and precision medicine field. It opens doors to a larger consumer and investor base interested in social impact and long-term profitability. The initiative is synergistically aligned with MGRC's expansive vision and focus on innovation.

As of 5 September 2023, MGRC’s share price is at RM0.52, with a market capitalisation of RM71.35 million.